On July 17, 2023 Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, reported the pricing of an underwritten offering of 4,153,717 shares of its common stock and pre-funded warrants to purchase 583,483 shares of common stock (Press release, Janux Therapeutics, JUL 17, 2023, View Source [SID1234633277]). The shares of common stock are being sold at a price of $12.46 per share and the pre-funded warrants are being sold at a price of $12.459 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Janux are expected to be approximately $60 million, before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on or about July 19, 2023, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BofA Securities, Inc. is acting as sole book-runner for the offering.

The shares are being offered by the company pursuant to a Registration Statement on Form S-3 previously filed and declared effective by the SEC. A final prospectus supplement and the accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed for free through the SEC’s website at www.sec.gov.

When available, a copy of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: BofA Securities, Inc., Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255, via telephone at (800) 294-1322 or via email at [email protected].

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of such state or jurisdiction.

On July 17, 2023 Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, reported an expanded collaboration with Sanofi (NASDAQ: SNY) (Press release, Scribe Therapeutics, JUL 17, 2023, View Source [SID1234633276]). Under the agreement, Sanofi receives an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo therapies, including sickle cell disease. The agreement follows the launch of the companies’ existing collaboration focused on ex vivo editing of natural killer (NK) cell therapies for the treatment of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The in vivo collaboration will leverage Scribe’s precisely engineered CRISPR XE technologies and Sanofi’s capabilities in non-viral delivery to address an initial target for sickle cell disease. Scribe’s proprietary CRISPR by Design approach powers the only platform that uses holistic engineering to transform bacterial immune systems into therapeutically relevant genome editing technologies. By combining Scribe’s novel technologies with Sanofi’s proven expertise in developing and manufacturing therapeutics on a global scale, the companies will seek to advance potentially breakthrough genomic medicines for the in vivo treatment of sickle cell and other diseases.

"We are continually impressed by the expertise, rigor, and urgency that Sanofi has brought to our existing ex vivo collaboration, as well as their rapid advancements and innovation in non-viral delivery technologies. Now, we are thrilled to expand our work together into new areas of high unmet need," said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe. "This in vivo collaboration further demonstrates the versatility of Scribe’s design-based approaches to CRISPR, which enable greater activity, specificity, and deliverability, ultimately accelerating the development of life-changing therapeutics."

By directly modifying genes within the body, Scribe’s tools for in vivo genome editing offer several key benefits over existing treatment options and late-stage investigational therapies. The innovative in vivo approach being explored under the collaboration has the potential to streamline the treatment process for sickle cell disease, minimizing complications associated with investigational ex vivo autologous treatments, such as conditioning regimen toxicities and a long, complex cell manufacturing process. Importantly, in vivo genome editing also promises to reduce both the cost and time required for treatment, thereby improving access for patients.

"We are pleased to expand our work with Scribe, an illustration of our shared commitment to advance best-in-class genome editing therapies for patients in need," said Christian Mueller, Global Head of Genomic Medicine Unit at Sanofi. "We’re encouraged by what we’ve accomplished to date with Scribe in creating ex vivo NK cell therapies and now look forward to accelerating our ability to effectively leverage genome editing in vivo through Sanofi’s innovative research work in targeted lipid nanoparticles (LNPs), for in vivo therapies with the potential to dramatically improve treatment outcomes and ultimately to change patients’ lives."

"Scribe’s platform holds tremendous potential to address an unprecedented number of therapeutically relevant targets across the human genome for many serious diseases," said Svetlana Lucas, Ph.D., Chief Business Officer at Scribe. "We are excited to partner with companies like Sanofi that offer not only disease and drug development expertise but also the resources and technologies enabling the delivery of our molecules in vivo to specific disease tissues, allowing us to develop better therapies. We look forward to our continued collaboration with Sanofi to expand the application of Scribe’s best-in-class genome editing tools and fully realize the promise of CRISPR for patients as broadly and rapidly as possible."

Deal Terms

Under the terms of the agreement, Scribe will receive $40 million in upfront payment and is eligible to potentially receive more than $1.2 billion based on the successful completion of certain development and sales milestones. Scribe will also be eligible to receive tiered royalties that range from high single digits to low double digits on net future sales on any products that may result from this agreement. Scribe has a right to opt-in to development cost sharing, as well as co-promotion and profit and loss sharing in the U.S. on one future program.

On July 17, 2023 CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, reported the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $5,000,000, before deducting underwriting discounts, and offering expenses (Press release, Cel-Sci, JUL 17, 2023, View Source [SID1234633275]). All of the shares of common stock are being offered by the Company. The offering is expected to close on July 20, 2023, subject to satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine* and for general corporate purposes.

ThinkEquity is acting as sole book-running manager for the offering.

The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-265995), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 1, 2022 and declared effective on July 15, 2022. The offering will be made only by means of a written prospectus. A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On July 17, 2023 GeneQuantum, a leading pioneer committed to innovative bioconjugation technology, and InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, reported to have signed a collaboration agreement (Press release, GeneQuantum Healthcare, JUL 17, 2023, View Source [SID1234633274]). GeneQuantum granted non-exclusive licensing of its proprietary conjugation technology to InxMed, supporting the development of the next generation of targeted conjugate ADC drugs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

According to the agreement, GeneQuantum will provide InxMed with its independently developed, globally leading technologies in site-specific glycan conjugation, stable linker small molecule technology, and intelligent continuous conjugation production platform. This will support InxMed in developing innovative ADC drugs. The agreement was signed following the successful concept validation results of the candidate drugs developed by both parties. After the agreement is signed, GeneQuantum will receive an upfront payment and will be eligible for milestone payments related to specific research and development progress and sales. They will also receive royalties based on the net commercial sales of the ADC products.

After the agreement is signed, InxMed will have the right to use GeneQuantum’s enzymatic site-specific conjugation technology on the candidate molecules mentioned above. InxMed will be responsible for the research, development, manufacturing, and commercialization of the ADC candidate molecules. This collaboration will enable both parties to leverage their respective technological advantages and resources, accelerate the research and development process of innovative ADC drugs, and provide more treatment options for patients worldwide.

Dr. Gang Qin, the founder and chairman of GeneQuantum, stated, "We are pleased to collaborate with InxMed. Founded by globally renowned clinical and translational medicine expert, Dr. Zaiqi Wang, InxMed possesses profound insights and extensive experience in target selection and innovative drug development. We are honored that InxMed has chosen GeneQuantum’s next-generation site-specific glycan conjugation technology (iGDC) after a comprehensive evaluation of global ADC conjugation technologies. Over the past decade, GeneQuantum has built a strong foundation in proprietary conjugation technology and integrated commercialization solutions. With iGDC as a leading example of the new generation of site-specific conjugation technology, GeneQuantum has gained significant industry attention and recognition. We believe that in combination with GeneQuantum’s intelligent continuous conjugation process technology, iGDC will empower a diverse range of monoclonal and bispecific antibodies with abundant target options, transforming them into leading biopharmaceutical conjugate therapies, achieving safe and efficient therapeutic outcomes. We will continue to maintain an open mindset, sharing resources and advantages with the upstream and downstream sectors of the innovative drug industry chain, and jointly build an industry ecosystem. We will spare no effort to support InxMed in advancing its core products to the clinical stage as quickly as possible."

Dr. Zaiqi Wang, founder, chairman, and CEO of InxMed, stated, "We are pleased to collaborate with GeneQuantum in this partnership. InxMed has made significant breakthroughs in the field of tumor resistance and metastasis. Through various types of drugs, including ADC, InxMed aims to better address this vast unmet clinical need."

On July 17, 2023 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that the broad claims of Compugen’s Anti-PVRIG Antibodies for use in treating cancer patent granted by the European Patent Office, which had been under opposition, have been successfully maintained (Press release, Compugen, JUL 17, 2023, View Source [SID1234633273]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppositions were pursued by GSK and an anonymous opponent represented by a third party against EP3258951B1. In an oral proceedings hearing on July 11 2023, the opposition division of the European Patent Office ruled in favor of maintaining the broad claims in the patent as granted to Compugen. The opponents can appeal this decision.

"We are delighted with the decision of the opposition division of the European Patent Office ruling in favor of maintenance of the broad claims in the patent as granted, supporting our patent strategy in novel target discovery." said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen.

Dr. Cohen-Dayag continued, "PVRIG is a novel immune checkpoint target, discovered by Compugen and along with TIGIT and PD-1 is part of the DNAM-1 axis. Our data suggest that in certain patients and in certain tumor types there is a need to block all three pathways in the DNAM-1 axis and we are currently leading the way in evaluating the triple blockade of PVRIG in combination with TIGIT and PD-1 in two proof of concept studies in tumors typically not responsive to immunotherapy, microsatellite stable colorectal cancer and platinum resistant ovarian cancer."

Compugen was represented by Markus Rieck, LL.M., Partner, Patent Attorney, Fuchs Patentanwälte Partnerschaft mbB and Thomas Wolter, Partner, Patent Attorney, Mewburn Ellis LLP.